{"protocolSection": {"identificationModule": {"nctId": "NCT03108027", "orgStudyIdInfo": {"id": "CQVM149B2209"}, "secondaryIdInfos": [{"id": "2017-000644-17", "type": "EUDRACT_NUMBER"}], "organization": {"fullName": "Novartis", "class": "INDUSTRY"}, "briefTitle": "Assess Bronchodilator Effect QVM149 Dosed Either in the Morning or Evening Compared to Placebo in Patients With Asthma", "officialTitle": "A Randomized, Double-blind, Repeat Dose Cross-over Study to Assess the Bronchodilator Effects of Once Daily QVM149 Following Morning or Evening Dosing for 14 Days Compared to Placebo in Patients With Asthma", "acronym": "QVM149"}, "statusModule": {"statusVerifiedDate": "2019-05", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2017-06-26", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2018-02-24", "type": "ACTUAL"}, "completionDateStruct": {"date": "2018-02-24", "type": "ACTUAL"}, "studyFirstSubmitDate": "2017-03-23", "studyFirstSubmitQcDate": "2017-04-04", "studyFirstPostDateStruct": {"date": "2017-04-11", "type": "ACTUAL"}, "resultsFirstSubmitDate": "2019-02-22", "resultsFirstSubmitQcDate": "2019-05-20", "resultsFirstPostDateStruct": {"date": "2019-05-21", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2020-12-09", "lastUpdatePostDateStruct": {"date": "2021-01-05", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Novartis Pharmaceuticals", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "This was a randomized, placebo-controlled, double-blind, six-sequence, three-period cross-over study in asthma patients. The study consisted of a 14-day screening period, followed by a 14-day run-in period, and a treatment epoch which consists of three treatment periods, with a minimum duration of 14 days each followed (for the 2 first treatment periods) by a wash-out period. The duration of each treatment period may be extended up to a duration of 18 days if needed for operational reasons. The third treatment period was followed by a Study Completion evaluation at 1-7 days following the last dose. The treatment periods were separated by wash-out periods of 14 to 21 days duration."}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["QVM149,", "asthma,", "allergic asthma,", "allergy triggered asthma,", "reactive asthma,", "asthma attack,", "difficulty breathing"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "CROSSOVER", "interventionModelDescription": "This study is to assess the bronchodilator effects of QVM149 dosed once daily either in the morning or in the evening for 2 weeks compared to placebo. It will provide evidence of the comparability of lung function effects of QVM149 irrespective of the administration schedule", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "maskingDescription": "This is a double-blind masking.", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 38, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Sequence 1", "type": "EXPERIMENTAL", "description": "Patients will receive in a sequential order the following interventional treatments: A,B and C.", "interventionNames": ["Drug: Treatment A: Matching placebo (morning dose) and QVM149 150/50/80 \u03bcg (evening dose)", "Drug: Treatment B: QVM149 150/50/80 \u03bcg (morning dose) and matching placebo (evening dose)", "Drug: Treatment C: Placebo (morning dose) and placebo (evening dose)"]}, {"label": "Sequence 2", "type": "EXPERIMENTAL", "description": "Patients will receive in a sequential order the following interventional treatments: B, A and C.", "interventionNames": ["Drug: Treatment A: Matching placebo (morning dose) and QVM149 150/50/80 \u03bcg (evening dose)", "Drug: Treatment B: QVM149 150/50/80 \u03bcg (morning dose) and matching placebo (evening dose)", "Drug: Treatment C: Placebo (morning dose) and placebo (evening dose)"]}, {"label": "Sequence 3", "type": "EXPERIMENTAL", "description": "Patients will receive in a sequential order the following interventional treatments: C, B and A.", "interventionNames": ["Drug: Treatment A: Matching placebo (morning dose) and QVM149 150/50/80 \u03bcg (evening dose)", "Drug: Treatment B: QVM149 150/50/80 \u03bcg (morning dose) and matching placebo (evening dose)", "Drug: Treatment C: Placebo (morning dose) and placebo (evening dose)"]}, {"label": "Sequence 4", "type": "EXPERIMENTAL", "description": "Patients will receive in a sequential order the following interventional treatments : C, A and B.", "interventionNames": ["Drug: Treatment A: Matching placebo (morning dose) and QVM149 150/50/80 \u03bcg (evening dose)", "Drug: Treatment B: QVM149 150/50/80 \u03bcg (morning dose) and matching placebo (evening dose)", "Drug: Treatment C: Placebo (morning dose) and placebo (evening dose)"]}, {"label": "Sequence 5", "type": "EXPERIMENTAL", "description": "Patients will receive in a sequential order the following interventional treatments: A, C and B.", "interventionNames": ["Drug: Treatment A: Matching placebo (morning dose) and QVM149 150/50/80 \u03bcg (evening dose)", "Drug: Treatment B: QVM149 150/50/80 \u03bcg (morning dose) and matching placebo (evening dose)", "Drug: Treatment C: Placebo (morning dose) and placebo (evening dose)"]}, {"label": "Sequence 6", "type": "EXPERIMENTAL", "description": "Patients will receive in a sequential order the following interventional treatments: B, C and A.", "interventionNames": ["Drug: Treatment A: Matching placebo (morning dose) and QVM149 150/50/80 \u03bcg (evening dose)", "Drug: Treatment B: QVM149 150/50/80 \u03bcg (morning dose) and matching placebo (evening dose)", "Drug: Treatment C: Placebo (morning dose) and placebo (evening dose)"]}], "interventions": [{"type": "DRUG", "name": "Treatment A: Matching placebo (morning dose) and QVM149 150/50/80 \u03bcg (evening dose)", "description": "Matching placebo (morning dose) and QVM149 150/50/80 \u03bcg (evening dose)", "armGroupLabels": ["Sequence 1", "Sequence 2", "Sequence 3", "Sequence 4", "Sequence 5", "Sequence 6"]}, {"type": "DRUG", "name": "Treatment B: QVM149 150/50/80 \u03bcg (morning dose) and matching placebo (evening dose)", "description": "QVM149 150/50/80 \u03bcg (morning dose) and matching placebo (evening dose)", "armGroupLabels": ["Sequence 1", "Sequence 2", "Sequence 3", "Sequence 4", "Sequence 5", "Sequence 6"]}, {"type": "DRUG", "name": "Treatment C: Placebo (morning dose) and placebo (evening dose)", "description": "Placebo (morning dose) and placebo (evening dose)", "armGroupLabels": ["Sequence 1", "Sequence 2", "Sequence 3", "Sequence 4", "Sequence 5", "Sequence 6"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "FEV1 Standardized Area Under the Curve (AUC 0-24h) After Last Evening Dose of 14-day Treatment Period", "description": "Weighted mean forced expiratory volume in 1 second (FEV1) over 24 h (AUC0-24h) following 14 days of treatment with QVM149 dosed in the morning, QVM149 dosed in the evening and placebo.", "timeFrame": "At the end of each treatment period day 14 pre-dose to 24 hours post-dose."}], "secondaryOutcomes": [{"measure": "Trough FEV1 After 24h", "description": "FEV1 at approximately 24 h after the last p.m. or penultimate a.m. dose. Morning and evening trough FEV1 (L) were analyzed by time of day. For morning trough FEV1 (L) assessments this meant that the spirometric assessment was done approximately 24 h after last morning dose and approximately 12 h after last evening dose.", "timeFrame": "At the end of each treatment period day 14 pre-dose to 24 hours post-dose."}, {"measure": "Peak Expiratory Flow (PEF)", "description": "Peak expiratory flow (PEF) is the maximum flow generated during a forceful exhalation, starting from full lung inflationDaily morning and evening peak expiratory flow rate from Day 2 to Day14 during the three treatment periods.", "timeFrame": "From treatment period start through study completion (up to 19 weeks)."}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\nPatients with a documented physician diagnosis of asthma and who additionally meet the following criteria:\n\n* Patients receiving daily treatment with an inhaled corticosteroid at a low or medium daily dose\n* On a stable regimen for at least 4 weeks prior to screening.\n* Pre-bronchodilator FEV1 \u2265 60 % and \\< 100% of the predicted normal value for the patient during screening.\n* Patients who demonstrate an increase in FEV1 of \u2265 12 % and \u2265 200 mL after administration of 400 \u03bcg salbutamol/360 \u03bcg albuterol (or equivalent dose) at Screening. All patients must perform a reversibility test at Screening.\n* At screening, and baseline (day 1 pre-dose time) of the first treatment period, vital signs (systolic and diastolic blood pressure and pulse rate) will be assessed in the sitting position and again in the standing position as outlined in the SOM. Sitting and standing vital signs should be within the following ranges:\n* oral body temperature between 35.0-37.5 \u00b0C\n* systolic blood pressure, 90-159 mmHg\n* diastolic blood pressure, 50-99 mmHg\n* pulse rate, 40-90 bpm\n* Hypertensive patients must have been on stable antihypertensive therapy for at least 4 weeks prior to screening to be included in the trial.\n* Patients must weigh at least 50 kg at screening to participate in the study, and must have a body mass index (BMI) within the range of 18 to 40 kg/m2.\n\nExclusion Criteria:\n\n* Contraindicated for treatment with, or having a history of reactions/ hypersensitivity to any of the drugs of a similar class\n* Patients who have had an asthma attack/exacerbation requiring systemic steroids or hospitalization or emergency room visit within 1 year of Screening.\n* Patients who have had previous intubation for a severe asthma ttack/exacerbation.\n* Patients with a history of clinically relevant bronchoconstriction upon repeated forced expiratory maneuvers.\n* History of paradoxical bronchospasm in response to inhaled medicines.\n* Patients who during the run-in period prior to randomization require the use of \u226512 puffs / 24 hours of rescue medication for 48 hours (over two consecutive days) or who have a decline in PEF from the reference PEFof \u2265 30% for 6 consecutive scheduled PEF readings\n* Patients who do not maintain regular day/night, waking/sleeping cycles (e.g., night shift workers).", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"locations": [{"facility": "Novartis Investigative Site", "city": "Berlin", "zip": "10117", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "Novartis Investigative Site", "city": "Frankfurt Am Main Hessen", "zip": "60596", "country": "Germany"}, {"facility": "Novartis Investigative Site", "city": "Grosshansdorf", "zip": "22947", "country": "Germany", "geoPoint": {"lat": 53.66667, "lon": 10.28333}}, {"facility": "Novartis Investigative Site", "city": "Hannover", "zip": "30625", "country": "Germany", "geoPoint": {"lat": 52.37052, "lon": 9.73322}}, {"facility": "Novartis Investigative Site", "city": "Wiesbaden", "zip": "65187", "country": "Germany", "geoPoint": {"lat": 50.08258, "lon": 8.24932}}, {"facility": "Novartis Investigative Site", "city": "Groningen", "state": "GZ", "zip": "9713", "country": "Netherlands", "geoPoint": {"lat": 53.21917, "lon": 6.56667}}, {"facility": "Novartis Investigative Site", "city": "Machester", "zip": "M23 9QZ", "country": "United Kingdom"}]}, "referencesModule": {"seeAlsoLinks": [{"label": "A Plain Language Trial Summary is available on novartisclinicatrials.com", "url": "https://www.novctrd.com/ctrdweb/patientsummary/patientsummaries?patientSummaryId=413"}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Sequence 1", "description": "Patients received in a sequential order the following interventional treatments: A,B and C."}, {"id": "FG001", "title": "Sequence 2", "description": "Patients received in a sequential order the following interventional treatments: B, A and C."}, {"id": "FG002", "title": "Sequence 3", "description": "Patients received in a sequential order the following interventional treatments: C, B and A."}, {"id": "FG003", "title": "Sequence 4", "description": "Patients received in a sequential order the following interventional treatments : C, A and B."}, {"id": "FG004", "title": "Sequence 5", "description": "Patients received in a sequential order the following interventional treatments: A, C and B."}, {"id": "FG005", "title": "Sequence 6", "description": "Patients received in a sequential order the following interventional treatments: B, C and A."}], "periods": [{"title": "Period 1", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "7"}, {"groupId": "FG001", "numSubjects": "6"}, {"groupId": "FG002", "numSubjects": "6"}, {"groupId": "FG003", "numSubjects": "6"}, {"groupId": "FG004", "numSubjects": "6"}, {"groupId": "FG005", "numSubjects": "6"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "7"}, {"groupId": "FG001", "numSubjects": "6"}, {"groupId": "FG002", "numSubjects": "6"}, {"groupId": "FG003", "numSubjects": "4"}, {"groupId": "FG004", "numSubjects": "6"}, {"groupId": "FG005", "numSubjects": "6"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "2"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}], "dropWithdraws": [{"type": "Subject/Guardian Decision", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "2"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}]}, {"title": "Period 2", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "7"}, {"groupId": "FG001", "numSubjects": "6"}, {"groupId": "FG002", "numSubjects": "6"}, {"groupId": "FG003", "numSubjects": "4"}, {"groupId": "FG004", "numSubjects": "6"}, {"groupId": "FG005", "numSubjects": "6"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "7"}, {"groupId": "FG001", "numSubjects": "6"}, {"groupId": "FG002", "numSubjects": "6"}, {"groupId": "FG003", "numSubjects": "4"}, {"groupId": "FG004", "numSubjects": "6"}, {"groupId": "FG005", "numSubjects": "6"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}]}, {"title": "Period 3", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "7"}, {"groupId": "FG001", "numSubjects": "6"}, {"groupId": "FG002", "numSubjects": "6"}, {"groupId": "FG003", "numSubjects": "4"}, {"groupId": "FG004", "numSubjects": "6"}, {"groupId": "FG005", "numSubjects": "6"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "7"}, {"groupId": "FG001", "numSubjects": "5"}, {"groupId": "FG002", "numSubjects": "6"}, {"groupId": "FG003", "numSubjects": "4"}, {"groupId": "FG004", "numSubjects": "6"}, {"groupId": "FG005", "numSubjects": "6"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "All Participants", "description": "All participants randomized to one of six treatment sequences"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "37"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "43.5", "spread": "14.04"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "16"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "21"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "35"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "2"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "FEV1 Standardized Area Under the Curve (AUC 0-24h) After Last Evening Dose of 14-day Treatment Period", "description": "Weighted mean forced expiratory volume in 1 second (FEV1) over 24 h (AUC0-24h) following 14 days of treatment with QVM149 dosed in the morning, QVM149 dosed in the evening and placebo.", "populationDescription": "The pharmacodynamic (PD) analysis set included all patients with any available PD data, who received any dose of study drug and experienced no protocol deviations with relevant impact on PD data.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liters", "timeFrame": "At the end of each treatment period day 14 pre-dose to 24 hours post-dose.", "groups": [{"id": "OG000", "title": "QVM149 am", "description": "QVM149 150/50/80 \u03bcg o.d. (indacaterol acetate 150 \u03bcg/ glycopyrronium bromide 50 \u03bcg/ MF 80 \u03bcg once daily) administered in the morning (plus matching placebo in the evening)"}, {"id": "OG001", "title": "QVM149 pm", "description": "QVM149 150/50/80 \u03bcg o.d. (indacaterol acetate150 \u03bcg/ glycopyrronium bromide 50 \u03bcg/ MF 80 \u03bcg once daily) administered in the evening (plus matching placebo in the morning)"}, {"id": "OG002", "title": "Placebo", "description": "Placebo administered in the morning and in the evening."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "30"}, {"groupId": "OG001", "value": "30"}, {"groupId": "OG002", "value": "33"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "3.4305", "spread": "0.15242"}, {"groupId": "OG001", "value": "3.4361", "spread": "0.15213"}, {"groupId": "OG002", "value": "2.8209", "spread": "0.15259"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "OTHER", "nonInferiorityComment": "A hypothesis test is not planned for this study, inferences are to be performed by interpreting confidence interval of treatment difference.'", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Net)", "paramValue": "0.6096", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.5380", "ciUpperLimit": "0.6811"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "OTHER", "nonInferiorityComment": "A hypothesis test is not planned for this study, inferences are to be performed by interpreting confidence interval of treatment difference.'", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Net)", "paramValue": "0.6152", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.5437", "ciUpperLimit": "0.6868"}, {"groupIds": ["OG000", "OG001"], "nonInferiorityType": "OTHER", "nonInferiorityComment": "A hypothesis test is not planned for this study, inferences are to be performed by interpreting confidence interval of treatment difference.'", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Net)", "paramValue": "-0.0057", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.0760", "ciUpperLimit": "0.0647"}]}, {"type": "SECONDARY", "title": "Trough FEV1 After 24h", "description": "FEV1 at approximately 24 h after the last p.m. or penultimate a.m. dose. Morning and evening trough FEV1 (L) were analyzed by time of day. For morning trough FEV1 (L) assessments this meant that the spirometric assessment was done approximately 24 h after last morning dose and approximately 12 h after last evening dose.", "populationDescription": "The pharmacodynamic (PD) analysis set included all patients with any available PD data, who received any dose of study drug and experienced no protocol deviations with relevant impact on PD data", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liters", "timeFrame": "At the end of each treatment period day 14 pre-dose to 24 hours post-dose.", "groups": [{"id": "OG000", "title": "QVM149 am", "description": "QVM149 150/50/80 \u03bcg o.d. (indacaterol acetate 150 \u03bcg/ glycopyrronium bromide 50 \u03bcg/ MF 80 \u03bcg once daily) administered in the morning (plus matching placebo in the evening)"}, {"id": "OG001", "title": "QVM149 pm", "description": "QVM149 150/50/80 \u03bcg o.d. (indacaterol acetate150 \u03bcg/ glycopyrronium bromide 50 \u03bcg/ MF 80 \u03bcg once daily) administered in the evening (plus matching placebo in the morning)"}, {"id": "OG002", "title": "Placebo", "description": "Placebo administered in the morning and in the evening."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "35"}, {"groupId": "OG001", "value": "35"}, {"groupId": "OG002", "value": "36"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "3.3731", "spread": "0.15037"}, {"groupId": "OG001", "value": "3.4871", "spread": "0.15041"}, {"groupId": "OG002", "value": "2.7524", "spread": "0.15120"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "OTHER", "nonInferiorityComment": "A hypothesis test is not planned for this study, inferences are to be performed by interpreting confidence interval of treatment difference.'", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Net)", "paramValue": "0.6206", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.5335", "ciUpperLimit": "0.7077"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "OTHER", "nonInferiorityComment": "A hypothesis test is not planned for this study, inferences are to be performed by interpreting confidence interval of treatment difference.'", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Net)", "paramValue": "0.7347", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.6469", "ciUpperLimit": "0.8225"}, {"groupIds": ["OG000", "OG001"], "nonInferiorityType": "OTHER", "nonInferiorityComment": "A hypothesis test is not planned for this study, inferences are to be performed by interpreting confidence interval of treatment difference.'", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Net)", "paramValue": "-0.1141", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.1970", "ciUpperLimit": "-0.0311"}]}, {"type": "SECONDARY", "title": "Peak Expiratory Flow (PEF)", "description": "Peak expiratory flow (PEF) is the maximum flow generated during a forceful exhalation, starting from full lung inflationDaily morning and evening peak expiratory flow rate from Day 2 to Day14 during the three treatment periods.", "populationDescription": "The pharmacodynamic (PD) analysis set included all patients with any available PD data, who received any dose of study drug and experienced no protocol deviations with relevant impact on PD data", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "L/min", "timeFrame": "From treatment period start through study completion (up to 19 weeks).", "groups": [{"id": "OG000", "title": "QVM149 am", "description": "QVM149 150/50/80 \u03bcg o.d. (indacaterol acetate 150 \u03bcg/ glycopyrronium bromide 50 \u03bcg/ MF 80 \u03bcg once daily) administered in the morning (plus matching placebo in the evening)"}, {"id": "OG001", "title": "QVM149 pm", "description": "QVM149 150/50/80 \u03bcg o.d. (indacaterol acetate150 \u03bcg/ glycopyrronium bromide 50 \u03bcg/ MF 80 \u03bcg once daily) administered in the evening (plus matching placebo in the morning)"}, {"id": "OG002", "title": "Placebo", "description": "Placebo administered in the morning and in the evening."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "35"}, {"groupId": "OG001", "value": "35"}, {"groupId": "OG002", "value": "36"}]}], "classes": [{"title": "Morning average PEF", "categories": [{"measurements": [{"groupId": "OG000", "value": "489.6", "spread": "19.77"}, {"groupId": "OG001", "value": "504.4", "spread": "19.78"}, {"groupId": "OG002", "value": "417.5", "spread": "19.73"}]}]}, {"title": "Evening average PEF", "categories": [{"measurements": [{"groupId": "OG000", "value": "522.0", "spread": "19.71"}, {"groupId": "OG001", "value": "507.7", "spread": "19.71"}, {"groupId": "OG002", "value": "449.0", "spread": "19.67"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "groupDescription": "Morning average PEF", "nonInferiorityType": "OTHER", "nonInferiorityComment": "A hypothesis test is not planned for this study, inferences are to be performed by interpreting confidence interval of treatment difference.'", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Net)", "paramValue": "72.1", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "61.3", "ciUpperLimit": "82.9"}, {"groupIds": ["OG001", "OG002"], "groupDescription": "Morning average PEF", "nonInferiorityType": "OTHER", "nonInferiorityComment": "A hypothesis test is not planned for this study, inferences are to be performed by interpreting confidence interval of treatment difference.'", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Net)", "paramValue": "86.9", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "76.1", "ciUpperLimit": "97.8"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Morning average PEF", "nonInferiorityType": "OTHER", "nonInferiorityComment": "A hypothesis test is not planned for this study, inferences are to be performed by interpreting confidence interval of treatment difference.'", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Net)", "paramValue": "-14.8", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-25.6", "ciUpperLimit": "-4.1"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Evening average PEF", "nonInferiorityType": "OTHER", "nonInferiorityComment": "A hypothesis test is not planned for this study, inferences are to be performed by interpreting confidence interval of treatment difference.'", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Net)", "paramValue": "73.1", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "61.9", "ciUpperLimit": "84.2"}, {"groupIds": ["OG001", "OG002"], "groupDescription": "Evening average PEF", "nonInferiorityType": "OTHER", "nonInferiorityComment": "A hypothesis test is not planned for this study, inferences are to be performed by interpreting confidence interval of treatment difference.'", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Net)", "paramValue": "58.7", "ciPctValue": "90", "ciLowerLimit": "47.5", "ciUpperLimit": "69.9"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Evening average PEF", "nonInferiorityType": "OTHER", "nonInferiorityComment": "A hypothesis test is not planned for this study, inferences are to be performed by interpreting confidence interval of treatment difference.'", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Net)", "paramValue": "14.4", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "3.3", "ciUpperLimit": "25.5"}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "Up to 19 weeks", "eventGroups": [{"id": "EG000", "title": "QVM149 a.m.", "description": "QVM149 150/50/80 \u03bcg o.d. (indacaterol acetate 150 \u03bcg/ glycopyrronium bromide 50 \u03bcg/ MF 80 \u03bcg once daily) administered in the morning (plus matching placebo in the evening)", "deathsNumAffected": 0, "deathsNumAtRisk": 35, "seriousNumAffected": 0, "seriousNumAtRisk": 35, "otherNumAffected": 11, "otherNumAtRisk": 35}, {"id": "EG001", "title": "QVM149 p.m.", "description": "QVM149 150/50/80 \u03bcg o.d. (indacaterol acetate150 \u03bcg/ glycopyrronium bromide 50 \u03bcg/ MF 80 \u03bcg once daily) administered in the evening (plus matching placebo in the morning)", "deathsNumAffected": 0, "deathsNumAtRisk": 35, "seriousNumAffected": 0, "seriousNumAtRisk": 35, "otherNumAffected": 13, "otherNumAtRisk": 35}, {"id": "EG002", "title": "Placebo", "description": "Placebo administered in the morning and in the evening", "deathsNumAffected": 0, "deathsNumAtRisk": 36, "seriousNumAffected": 0, "seriousNumAtRisk": 36, "otherNumAffected": 16, "otherNumAtRisk": 36}], "otherEvents": [{"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 35}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 35}, {"groupId": "EG002", "numAffected": 5, "numAtRisk": 36}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 35}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 35}, {"groupId": "EG002", "numAffected": 7, "numAtRisk": 36}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 35}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 35}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 36}]}, {"term": "Dysphonia", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 35}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 35}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 36}]}, {"term": "Oropharyngeal pain", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 35}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 35}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 36}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety"}, "pointOfContact": {"title": "Study Director", "organization": "Novartis Pharmaceutical", "email": "novartis.email@novartis.com", "phone": "862-778-8300"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "SAP", "hasProtocol": false, "hasSap": true, "hasIcf": false, "label": "Statistical Analysis Plan", "date": "2018-03-27", "uploadDate": "2019-02-22T08:21", "filename": "SAP_000.pdf", "size": 2105944}, {"typeAbbrev": "Prot", "hasProtocol": true, "hasSap": false, "hasIcf": false, "label": "Study Protocol", "date": "2017-03-08", "uploadDate": "2019-02-22T08:21", "filename": "Prot_001.pdf", "size": 3036481}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M27137", "name": "Respiratory Aspiration", "relevance": "LOW"}, {"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M7591", "name": "Dyspnea", "relevance": "LOW"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}, {"id": "T4202", "name": "Oculocerebral Syndrome With Hypopigmentation", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}, "interventionBrowseModule": {"browseLeaves": [{"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}